Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 16,300 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) insider David Raben sold 16,300 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the completion of the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,023,896.72. This represents a 22.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

David Raben also recently made the following trade(s):

• On Tuesday, March 3rd, David Raben sold 200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.45, for a total value of $3,690.00.

Bicara Therapeutics Stock Down 0.2%

Shares of BCAX traded down $0.04 during trading hours on Thursday, hitting $18.50. The stock had a trading volume of 950,200 shares, compared to its average volume of 516,872. The company’s fifty day moving average is $16.43 and its two-hundred day moving average is $15.70. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $19.71.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC acquired a new position in Bicara Therapeutics in the third quarter valued at $481,000. Artisan Partners Limited Partnership acquired a new position in Bicara Therapeutics during the 2nd quarter worth approximately $3,742,000. Skandinaviska Enskilda Banken AB publ boosted its holdings in Bicara Therapeutics by 160.9% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock worth $922,000 after acquiring an additional 61,201 shares in the last quarter. Schroder Investment Management Group grew its stake in Bicara Therapeutics by 921.0% in the second quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after acquiring an additional 383,681 shares during the period. Finally, SCS Capital Management LLC acquired a new position in shares of Bicara Therapeutics during the second quarter worth approximately $496,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Citigroup assumed coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating on the stock. Finally, Citizens Jmp initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.